Filing Overview
Filing and period: Form 10-Q for the quarter ended March 31, 2024, filed May 8, 2024. The source filing identifies the registrant as Aadi Bioscience, Inc., not Whitehawk Therapeutics, Inc.; this company identity should be verified.
Aadi is a commercial-stage biopharmaceutical company focused on precision therapies targeting the mTOR pathway. Its lead product, FYARRO, is approved in the United States for advanced malignant PEComa and was launched in February 2022.
Financial Performance and Position
| Metric | Q1 2024 | Q1 2023 | Change |
|---|---|---|---|
| Net product sales | $5.353 million | $5.867 million | Down $0.514 million |
| SG&A expense | $10.620 million | $11.207 million | Down $0.587 million |
| R&D expense | $13.593 million | $10.956 million | Up $2.637 million |
| Cost of goods sold | $0.652 million | $0.529 million | Up $0.123 million |
| Operating loss | $19.512 million | $16.825 million | Loss increased $2.687 million |
| Net loss | $18.289 million | $15.223 million | Loss increased $3.066 million |
| Net loss per share | $0.68 | $0.57 | Loss per share increased |
| Operating cash flow | $(19.653) million | $(21.310) million | Use decreased $1.657 million |
Margins: Product sales less cost of goods sold imply an approximate product gross margin of 87.8% in Q1 2024 versus approximately 91.0% in Q1 2023. The company remained materially unprofitable; the filing does not present a separate adjusted EBITDA measure.
- Cash and cash equivalents were $53.780 million at March 31, 2024, compared with $62.888 million at December 31, 2023.
- Short-term investments were $34.491 million, down from $45.957 million. Total cash, cash equivalents and short-term investments were approximately $88.3 million.
- Total assets were $111.073 million and total liabilities were $20.613 million.
- Accumulated deficit was $287.252 million.
- The company reported no income tax expense and maintains a full valuation allowance on deferred tax assets.
- Net cash provided by investing activities was $10.555 million, primarily from $18.940 million of investment maturities, partly offset by $7.646 million of investment purchases and $0.739 million of capital expenditures.
- There was no conventional long-term debt reported, but the company had a $5.757 million due-to-licensor payable, plus accrued interest, due August 26, 2024.
Material Changes Versus the Prior Comparable Period
- FYARRO sales declined 8.8%, which management attributed to distributor ordering patterns and fewer new patient initiations than the historical average.
- R&D expense increased 24.1%, primarily due to higher clinical development spending related to the PRECISION1 trial and increased clinical drug-product manufacturing costs.
- SG&A expense decreased 5.2%, primarily because of lower consulting, legal and other costs, partly offset by $1.3 million of higher personnel expense related mainly to severance from a workforce reduction and restructuring.
- Net loss increased 20.1%, reflecting the higher R&D spending and lower product sales.
- Operating cash burn improved from $21.310 million to $19.653 million, although cash, cash equivalents and restricted cash decreased by $9.108 million during the quarter.
- Share-based compensation increased to $3.589 million from $2.740 million. Outstanding options increased to 5.373 million shares from 4.580 million at January 1, 2024, while 341,258 restricted stock units were outstanding at quarter-end.
Guidance, Outlook, Risks and Unusual Items
- Management stated that existing cash, cash equivalents and short-term investments are expected to fund planned operations into the fourth quarter of 2025. The notes more generally state that liquidity is sufficient for at least twelve months from the filing date.
- The PRECISION1 trial was fully enrolled in April 2024, is expected to be completed by year-end 2024, and results are anticipated in early 2025. The company expected to report a two-thirds interim analysis in the third quarter of 2024.
- The company continued Phase 2 programs evaluating FYARRO in endometrioid endometrial cancer and neuroendocrine tumors.
- In May 2024, after the quarter-end, the company and Mirati mutually terminated their collaboration and discontinued the Phase 1/2 adagrasib-FYARRO study. Aadi stated that resources would be prioritized for the endometrial cancer and neuroendocrine tumor programs.
- The Fresenius Kabi supply agreement was amended effective March 2024. It includes minimum purchase commitments and non-cancellable inventory commitments of $3.8 million payable during 2024. The agreement was extended to July 31, 2024, or a later date agreed by the parties.
- Aadi relies on Fresenius Kabi as its single-source manufacturer for FYARRO and has no alternative manufacturer currently in place, creating supply and continuity risk.
- The company is party to ongoing arbitration initiated by EOC concerning termination of the FYARRO license agreement. EOC seeks monetary damages, but Aadi cannot estimate the possible loss or range of loss and has accrued no liability.
- The company had an effective $75 million at-the-market common-stock sales agreement with Cowen, but no shares had been sold under it as of March 31, 2024. A $150 million universal shelf registration statement became effective April 30, 2024; no securities had been sold under it as of the filing.
- Key risks include continued operating losses, potential need for additional financing and dilution, uncertain clinical and regulatory outcomes, limited market opportunity for rare cancers, reimbursement and pricing pressure, dependence on third-party manufacturers and suppliers, intellectual-property and licensing risks, litigation, and stock-price volatility.
- Management reported that disclosure controls and procedures were effective as of March 31, 2024, with no material changes in internal control over financial reporting during the quarter.
Most Important Facts for Investors to Verify
- Confirm the registrant’s identity because the supplied metadata names Whitehawk Therapeutics, while the filing is for Aadi Bioscience, Inc.
- Track FYARRO sales, channel inventory, patient initiations and gross-to-net deductions, given the Q1 sales decline and concentration of revenue among two customers.
- Assess cash burn against the stated fourth-quarter 2025 runway, including the $5.8 million licensor balloon payment due August 2024 and ongoing clinical spending.
- Monitor PRECISION1 enrollment completion, interim data, trial completion and anticipated early-2025 results, as well as the endometrial cancer and neuroendocrine tumor programs.
- Review the outcome and potential financial exposure of the EOC arbitration, for which no loss has been accrued.
- Verify continuation or renegotiation of the Fresenius Kabi supply agreement and the company’s ability to satisfy minimum purchase commitments.
- Evaluate potential equity financing, dilution and compliance with Form S-3 “baby shelf” limitations if additional capital is required.